{"groups":[{"description":"brentuximab vedotin 1.8 mg/kg every 3 weeks by IV infusion","id":"FG000","title":"Brentuximab Vedotin"},{"description":"placebo every 3 weeks by IV infusion","id":"FG001","title":"Placebo"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"18"},{"groupId":"FG001","numSubjects":"25"}],"type":"Withdrawal by Subject"},{"reasons":[{"groupId":"FG000","numSubjects":"13"},{"groupId":"FG001","numSubjects":"28"}],"type":"Lost to Follow-up"},{"reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"1"}],"type":"Site request to end participation in study"},{"reasons":[{"groupId":"FG000","numSubjects":"45"},{"groupId":"FG001","numSubjects":"40"}],"type":"Death"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"165"},{"groupId":"FG001","numSubjects":"164"}],"type":"STARTED"},{"achievements":[{"comment":"Completed due to study closure by sponsor","groupId":"FG000","numSubjects":"89"},{"comment":"Completed due to study closure by sponsor","groupId":"FG001","numSubjects":"70"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"76"},{"groupId":"FG001","numSubjects":"94"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"recruitmentDetails":"Apr 2010-Aug 2014"}